NCT05740202View on ClinicalTrials.gov

A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

SHR-7367

The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors.

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY